BalanCD HEK293 Perfusion A enables process optimisation by enhancing cell growth, viability, and productivity
Fujifilm Biosciences, specialists in developing and manufacturing cell solutions for the Life Science market, have commercially launched the BalanCD HEK293 Perfusion A.
Created to expand and augment the company's portfolio of gene therapy application solutions, BalanCD HEK293 Perfusion A uses suspension HEK293 cells and perfusion technology to provide reliable, efficient, and scalable production of viral vectors for the development of gene therapies.
HEK293 cells are well established for gene therapy applications in upstream bioprocessing, offering reliable growth rates, high transfection success, and expression of cellular factors necessary for virus replication.
BalanCD HEK293 Perfusion A enables process optimisation by enhancing cell growth, viability, and productivity. It supports a wide range of applications, including viral vector production, transient protein expression, and recombinant protein production.
The medium has been designed for high-density perfusion culture, demonstrating compatibility across various cell retention devices, and offers versatility across workflows. It is available in multiple media package options for continuous processing and optimal performance. The BalanCD HEK293 Perfusion A medium is also compatible with different types of transfection methods and suited for both steady-state and intensified perfusion processes.
By utilising perfusion technology, the product helps reduce overall capital expenditures associated with AAV and LV production, key virus types for in vivo and in vitro gene transfer. This maximises resources for consistency and scalability, while providing clinical-quality media able to support large commercial batch sizes for advanced therapy development.
Erik Vaessen, chief business officer at Fujifilm Biosciences, said, “Fujifilm Biosciences is committed to helping our partners bring innovative new treatments and therapies to more patients than ever before. With BalanCD HEK293 Perfusion A medium, we have introduced a new way to advance gene therapies, building on a family of purposely-designed, high-performing HEK293 products to provide more consistent, high-quality resources across the treatment spectrum. This innovative approach is another example on how we are customising services, products, and systems to help all who bring therapeutics to more patients, as we continue to work on this mission together.”
